HMNC Brain Health has secured $50 million in a Series B fundraise designed to support two psychiatry programs into mid-stage studies.
HMNC Brain Health has secured $50 million in a Series B fundraise designed to support two psychiatry programs into mid-stage studies.
The family-owned German drugmaker …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Biotech: Pharmakonzern Medice steigt bei HMNC Brain Health ein
Neumora depression drug fails; EnGene to cut 50% of staff
ARCH-launched Neumora stops depression program
FDA appears open to Moderna's flu vaccine ahead of adcomm
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD
Positive Results From The Phase Ib Clinical Study of NeuroRestore ACD856, Under Development for Alzheimer's
Die Biotechfirma sammelt 50 Millionen Dollar Finanzierung ein, wie das Handelsblatt exklusiv erfuhr. Hauptinvestor ist Medice.…
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing…
Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss;…
A new AI model to improve trial enrollment, importing drugs from Canada, and more biotech news from The Readout
